Compare Moderna, Inc. (MRNA) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Ross Stores, Inc. — how do they compare? Moderna, Inc. trades at $215.35 (market cap $78.65B), while Ross Stores, Inc. trades at $221.83 (market cap $71.94B). The key difference: Moderna, Inc. and Ross Stores, Inc. are close in size by market cap, and Ross Stores, Inc. pays a 0.79% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Ross Stores, Inc. for 48 Days on average.
| MRNA | ROST | |
|---|---|---|
Market Cap | $78.65B | $71.94B |
Volume | 37,373,437 | 2,002,519 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $255.23 |
52-Week Low | $22.36 | $147.71 |
Typical Hold Time | 59 Days | 48 Days |
Enterprise Value | $74.80B | $72.39B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Ross Stores (ROST) trades at $225.53, up 0.59% with strong fundamental performance including three consecutive earnings beats and robust profitability metrics. The stock shows bearish technical signals despite positive analyst sentiment, with 64% buy ratings and a $274.14 consensus price target representing 22% upside potential. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents compelling investment potential with strong earnings momentum and expanding profit margins, though technical weakness and competitive pressures warrant caution. The company's value-focused strategy and operational discipline support continued growth, while elevated valuation multiples and market volatility pose near-term risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
